Search results for: rare disease

UK first rare disease action plan

On 28th February 2022, Health and Social Care Secretary Sajid Javid launched England’s first Rare...

Read more
Access for rare disease treatments

Innovative therapies for rare diseases may only be available in a select number of countries in Euro...

Read more
What is HST

NICE’s Highly-Specialised Technologies (HST) process is a method for evaluating medicines and trea...

Read more
Top 20 most expensive drugs in US

Top 20 most expensive drugs in the US.

Read more
Orphan Drugs and Diseases: 101

This article discusses updates to the orphan drugs and diseases landscapes, the challenges and incen...

Read more
Treatment for rare conditions

Faster access to new treatments for very rare conditions announced following a revised decision maki...

Read more
HAS relaxes evidence requirements under certain co...

New doctrine accelerates drug development for rare diseases and oncology by adjusting evidence requi...

Read more
Changes to NICE's health technology evaluation

This reforms have been welcomed by the industry as they should support faster access to medicines as...

Read more
NICEs Highly Specialised Technologies Process

With many anticipated new medicines for rare diseases, countries are beginning to prepare appropriat...

Read more
An analysis of the top 20 most expensive drugs

This study investigates costs of gene/acute therapies versus chronic treatments for rare diseases, o...

Read more
Older
Newer

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.

Talk to an expert

Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​

Get in touch